PET-CTNCT07259941
PET-CT in Lymphoma Among the Eldery
An observational study of PET-CT and Lymphoma, run by Assiut University.
Trial summary
This study investigates PET-CT imaging patterns and metabolic parameters in elderly patients (≥60 years) diagnosed with lymphoma, aiming to enhance diagnostic accuracy and prognosis using 18F-FDG PET/CT scans. Read more about this study
- Who is it for?
- Ages 60 years and older
- How many people
- 63 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2026to 1 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Adult, Older adult
Study population: The participants include elderly patients (≥60 years) with confirmed lymphoma diagnosis through histopathological examination. Excluded are individuals with other active cancers or uncontrolled diabetes mellitus (blood glucose > 200 mg/dL), which could interfere with PET scan accuracy. Patients must have fasting blood glucose < 200 mg/dL before 18F-FDG injection and are prepared per standardized protocols. The sample size is calculated to be approximately 63 patients, providing adequate statistical power based on confidence limits and previous positive PET findings in elderly lymphoma cohorts.
Who may be able to join
- Age ≥ 60 years
- Histopathological diagnosis of lymphoma
Who cannot join
- Presence of other concurrent active malignancies
- Uncontrolled diabetes mellitus with blood glucose > 200 mg/dL at the time of PET/CT scan
About this study
Official title: PET-CT Imaging Findings and Metabolic Parameters in Elderly Patients With Lymphoma
This study investigates PET-CT imaging patterns and metabolic parameters in elderly patients (≥60 years) diagnosed with lymphoma, aiming to enhance diagnostic accuracy and prognosis using 18F-FDG PET/CT scans.
Read the detailed description
This cross-sectional study involves both retrospective and prospective data collection from elderly lymphoma patients (aged 60 years or older) at the Nuclear Medicine Unit, South Egypt Cancer Institute. It evaluates the PET-CT imaging findings alongside metabolic parameters such as Standardized Uptake Value (SUV), Metabolic Tumor Volume (MTV), and Total Lesion Glycolysis (TLG). The study addresses diagnostic challenges in elderly patients due to atypical presentations and comorbidities and fills the gap of scarce local data in Egypt. Imaging analysis includes visual and semiquantitative assessment of lymphatic and extranodal lesions post-injection of 18F-FDG, assessing tumor metabolic activity to provide prognostic insights. Data analysis uses SPSS with relevant statistical tests to validate findings.
- Conditions
- PET-CT, Lymphoma, Elderly, Metabolic Parameters
- Keywords
- PET-CT, Lymphoma, Elderly, metabolic parameters
- Medical subject headings
- Lymphoma
What is being measured
The primary outcome is the main question the study is designed to answer.
FDG-PET/CT Imaging Pattern Description in Elderly Lymphoma Patients
The main outcome is the characterization of metabolic and anatomical findings from 18F-FDG PET/CT scans among elderly patients (≥60 years) diagnosed with lymphoma. This includes describing the visual appearance, extent, and distribution of disease lesions observed on initial imaging.
Measured: At time of initial PET/CT scan performed as part of routine clinical evaluation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2025
- Study start1 Jan 2026 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PET-CTStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 63 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marwa Mamdouh Ekram, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07259941
- Sponsor's protocol ID
- PET-CT Imaging in Lymphoma
- Status last verified
- Nov 2025
- First submitted
- 21 Nov 2025
- Last updated
- 2 Dec 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PET-CT Imaging Findings and Metabolic Parameters in Elderly Patients With Lymphoma
- ClinicalTrials.gov ID
- NCT07259941
- Acronym / sponsor ID
- PET-CT Imaging in Lymphoma
- Conditions
- PET-CT, Lymphoma, Elderly, Metabolic Parameters
- Keywords
- PET-CT, Lymphoma, Elderly, metabolic parameters
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 63 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 2 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates PET-CT imaging patterns and metabolic parameters in elderly patients (≥60 years) diagnosed with lymphoma, aiming to enhance diagnostic accuracy and prognosis using 18F-FDG PET/CT scans.
Detailed description
This cross-sectional study involves both retrospective and prospective data collection from elderly lymphoma patients (aged 60 years or older) at the Nuclear Medicine Unit, South Egypt Cancer Institute. It evaluates the PET-CT imaging findings alongside metabolic parameters such as Standardized Uptake Value (SUV), Metabolic Tumor Volume (MTV), and Total Lesion Glycolysis (TLG). The study addresses diagnostic challenges in elderly patients due to atypical presentations and comorbidities and fills the gap of scarce local data in Egypt. Imaging analysis includes visual and semiquantitative assessment of lymphatic and extranodal lesions post-injection of 18F-FDG, assessing tumor metabolic activity to provide prognostic insights. Data analysis uses SPSS with relevant statistical tests to validate findings.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The participants include elderly patients (≥60 years) with confirmed lymphoma diagnosis through histopathological examination. Excluded are individuals with other active cancers or uncontrolled diabetes mellitus (blood glucose > 200 mg/dL), which could interfere with PET scan accuracy. Patients must have fasting blood glucose < 200 mg/dL before 18F-FDG injection and are prepared per standardized protocols. The sample size is calculated to be approximately 63 patients, providing adequate statistical power based on confidence limits and previous positive PET findings in elderly lymphoma cohorts.
Key inclusion criteria (2 listed)
- Age ≥ 60 years
- Histopathological diagnosis of lymphoma
Key exclusion criteria (2 listed)
- Presence of other concurrent active malignancies
- Uncontrolled diabetes mellitus with blood glucose > 200 mg/dL at the time of PET/CT scan
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
FDG-PET/CT Imaging Pattern Description in Elderly Lymphoma Patients
Time frame: At time of initial PET/CT scan performed as part of routine clinical evaluation
The main outcome is the characterization of metabolic and anatomical findings from 18F-FDG PET/CT scans among elderly patients (≥60 years) diagnosed with lymphoma. This includes describing the visual appearance, extent, and distribution of disease lesions observed on initial imaging.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2025.
Related trials for PET-CT
RecruitingEarly Phase 1
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
Cushing Disease, Pituitary Adenoma
RecruitingPhase 1
First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers
Healthy
Recruiting
F-18 Sodium Fluoride PET/CT-Guided Pain Palliation in Chronic Plantar Fasciitis: A Comparative Study of ¹⁷⁷Lutetium-Corticosteroid-Local Anaesthetic Injection vs Corticosteroid-Local Anaesthetic Injection
Plantar Fascitis, Chronic Heel Pain
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
RecruitingPhase 2
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of PET-CT and Lymphoma, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FDG-PET/CT Imaging Pattern Description in Elderly Lymphoma Patients (time frame: At time of initial PET/CT scan performed as part of routine clinical evaluation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.